Metabolic fate of milk glycosaminoglycans in breastfed and formula fed newborns
In this study, the content, structure and residual percentages of glycosaminoglycans (GAGs) in the feces of seven breastfed newborns after ingesting a known amount of milk were studied. A comparison was made with five newborns fed with formula milk. Characterization of GAGs from milk and feces samples was performed according to previous methodology. Compared to the ingested GAGs present in milk, residual feces GAGs of breastfed newborns were <0.4 %, contrary to formula milk fed children, where the residues were ~4 %. As a consequence, >99 % of human milk GAGs are utilized as opposed to ~96 % of formula milk. Hyaluronic acid utilization was found to be fairly similar contrary to chondroitin sulfate/dermatan sulfate and heparan sulfate, which were found to be ~10–18 times lower in formula milk fed children. Our new results further demonstrate that the elevated content of human milk GAGs passes undigested through the entire digestive system of newborns, possibly protecting the infant from infections. In the distal gastrointestinal tract, these complex macromolecules are catabolized by a cohort of bacterial enzymes and constituent monosaccharides/oligosaccharides utilized for further metabolic purposes potentially useful for bacteria metabolism or internalized by intestinal cells. Thanks to their elevated structural heterogeneity, milk GAGs are used differently depending on their distinct primary structure. Finally, a different utilization and availability was observed for human milk GAGs compared to formula milk due to their various composition and structural heterogeneity.
KeywordsNewborn feces Human milk Glycosaminoglycans Hyaluronic acid Chondroitin sulfate Heparan sulfate Breastfeeding
N.V. developed the applied methodologies. F.M., V.M., L.Z., T.G. and F.G. performed the experimental procedures and analyses. A.C. collected the feces samples. N.V., G.V.C. and O.G. designed and developed the experimental design, performed data analysis and wrote the manuscript.
All authors reviewed and approved the study.
Compliance with ethical standards
Conflicts of interest
We declare that we have no conflicts of interest.
- 5.Newburg D.S., Linhardt R.J., Ampofo S.A., Yolken R.H.: Human milk glycosaminoglycans inhibit HIV glycoprotein gp120 binding to its host cell CD4 receptor. J Nutrition. 125, 419–424 (1995)Google Scholar
- 13.Coppa GV, Facinelli B, Magi G, Marini E, Zampini L, Mantovani V, Galeazzi T, Padella L, Marchesiello RL, Santoro L, Coscia A, Peila C, Volpi N, Gabrielli O. Human Milk Glycosaminoglycans Inhibit in vitro the Adhesion of Escherichia coli and Salmonella fyris to Human Intestinal Cells. Ped Res In Press (2016).Google Scholar
- 14.Hill D.R., Rho H.K., Kessler S.P., Amin R., Homer C.R., McDonald C., Cowman M.K., de la Motte C.A.: Human milk hyaluronan enhances innate defense of the intestinal epithelium. J. Biolumin. Chemilumin. 288, 29090–29104 (2013)Google Scholar
- 17.Galeotti F., Volpi N.: Online reverse phase-high-performance liquid chromatography-fluorescence detection-electrospray ionization-mass spectrometry separation and characterization of heparan sulfate, heparin, and low-molecular weight-heparin disaccharides derivatized with 2-aminoacridone. Anal. Chem. 83, 6770–6777 (2011)CrossRefPubMedGoogle Scholar
- 30.Ulmer J.E., Vilén E.M., Namburi R.B., Benjdia A., Beneteau J., Malleron A., Bonnaffé D., Driguez P.A., Descroix K., Lassalle G., Le Narvor C., Sandström C., Spillmann D., Berteau O.: Characterization of Glycosaminoglycan (GAG) Sulfatases from the Human Gut Symbiont Bacteroides thetaiotaomicron Reveals the First GAG-specific Bacterial Endosulfatase. J. Biolumin. Chemilumin. 289, 24289–24303 (2014)Google Scholar
- 33.Volpi N., Gabrielli O., Carlucci A., Zampini L., Santoro L., Padella L., Marchesello R.L., Maccari F., Coppa G.V.: Human milk glycosaminoglycans in feces of breastfed newborns: preliminary structural elucidation and possible biological role. Breastfeed. Med. 9, 105–106 (2014)CrossRefPubMedGoogle Scholar